EpicGenetics, with the Assistance of Leading Medical
Centers, Expands Clinical Study of FM/a® Test to Diagnose Fibromyalgia,
Identify Genetic Markers Unique to the Disorder and Explore Direct Treatment
Approaches
- Provides
Research Gift to the Faustman Immunobiology Lab at
Massachusetts
General Hospital/Harvard Medical School to
Support Research
on Fibromyalgia Treatments -
In February of 2016, I wrote a blog on the
importance of a well-designed study on fibromyalgia, Are
Fibromyalgia Researchers on a Common Path?
In June of 2016, I wrote a blog on my
personal experience with the FM/a® blood test providing a detailed
guideline on how the process worked for me, and my results.
In an article that will be published soon
by ProHealth, I write about the chaos surrounding concrete diagnostic criteria
and the disparaging consequences.
Breaking
News
And now I am excited to write about new
research that could very well provide us with a true understanding of a “disease”
called fibromyalgia.
I have been waiting for permission to
share what you are about to read.
LOS ANGELES – April 19, 2017 – EpicGenetics, a
privately held biomedical company dedicated to improving the diagnosis and
treatment of fibromyalgia, today announced that it has engaged the University
of California, Los Angeles (UCLA)* and the University of Illinois College of
Medicine Chicago (UIC). Both university research centers will be sequencing the
exomes of patients to improve the diagnosis of fibromyalgia through the
application of the FM/a® Test and to allow EpicGenetics to detect fibromyalgia
disease-specific gene markers. Additionally, Bruce Gillis, M.D., CEO of
EpicGenetics, has made a research gift to the Immunobiology Laboratory at the
Massachusetts General Hospital directed by Denise Faustman, M.D., Ph.D., to
continue its robust clinical research regarding a direct treatment for
fibromyalgia.
The FM/a® Test is an FDA-compliant blood test that
diagnoses fibromyalgia by identifying the presence of specific white blood cell
abnormalities that have been documented to exist in these patients. The FM/a®
Test accurately and objectively diagnoses this chronic disorder that afflicts
millions of men, women and children.
Committment
I have been committed to understanding and
educating my peers on fibromyalgia over the past two decades, but I have never
been as excited as I am right now. To be part of a study that has the potential
to prove fibromyalgia as a disease with definite treatments is probably the
pinnacle of my work.
Dr.
Gillis Is Committed
About this announcement, Dr. Gillis told
me, “We are hoping to finally bring our understanding of fibromyalgia out of
the Dark Ages. Millions of women, men and children suffer from fibromyalgia,
yet our understanding and acknowledgement of this as a legitimate medical
condition is still so limited and has not advanced in a meaningful way in
decades. With the clinical efforts being initiated as part of today’s
announcement, we hope to finally change this and, ultimately, we are seeking to
provide answers and better solutions for people who suffer from fibromyalgia.”
Follow @TheFMTest on Facebook
What
is “Campaign 250?”
According to Epicgenetics, Campaign 250 represents the largest and most
ambitious study to investigate fibromyalgia’s genetic origins, as well as
develop a treatment protocol addressing the underlying biology of the disease.
 |
| Download PDF at https://drive.google.com/file/d/0B6iFloW6MyVwakttOHFGUWpRNkk/view?usp=sharing |
Under contract with researchers from both
UCLA* and the University of Illinois College of Medicine Chicago, Campaign 250
will conduct Whole-Exome genetic testing
on up to 250,000 patients who have received a positive FM/a® fibromyalgia
diagnosis. All direct testing costs will be covered by EpicGenetics**.
Based upon the findings of this testing and once treatment protocols have
received regulatory and institutional approvals, FM/a® Test positive
patients will be invited to participate in a fibromyalgia-specific vaccine clinical trial to reverse the biology
of fibromyalgia. The vaccine trial will be conducted in cooperation with The
Faustman Lab and Dr. Denise Faustman at the Massachusetts General
Hospital/Harvard School of Medicine, the clinical trial will seek to alleviate
fibromyalgia-related symptoms…
* The David Geffen School of Medicine at
UCLA has been engaged to sequence the exomes of research subjects
**The genetic tests will require a $45 administration fee to cover the processing of the test, which is a $2,500+ cost being provided at no charge.
**The genetic tests will require a $45 administration fee to cover the processing of the test, which is a $2,500+ cost being provided at no charge.
Participation
I am anxious to see if I carry the
fibromyalgia gene and I am honored to participate in providing information that
can make a difference in the lives of people all over the world who live with
fibromyalgia. I hope you can join me on this
next chapter.
“The mighty oak
was once a little nut that stood its ground.”
--Unknown
Additional Information:
FM/a®
Blood Test – “How To” – My detailed account of the process
(Signature
line appended July 2018)
In healing,
Celeste Cooper, RN / Author, Freelancer, Advocate
Think adversity?-See opportunity!
~ • ~ • ~ • ~ • ~ • ~
Learn more about
Celeste’s books here. Subscribe
to posts by using the information in the upper right hand corner or use the
share buttons to share with others.
Posts
